A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1(T315I) in Ph+ CML

In chronic myeloid leukemia (CML), resistance against second-generation tyrosine kinase inhibitors (TKI) remains a serious clinical challenge, especially in the context of multi-resistant BCR-ABL1 mutants, such as T315I. Treatment with ponatinib may suppress most of these mutants, including T315I, b...

全面介紹

Na minha lista:
書目詳細資料
發表在:Leuk Res
Main Authors: Gleixner, Karoline V., Sadovnik, Irina, Schneeweiss, Mathias, Eisenwort, Gregor, Byrgazov, Konstantin, Stefanzl, Gabriele, Berger, Daniela, Herrmann, Harald, Hadzijusufovic, Emir, Lion, Thomas, Valent, Peter
格式: Artigo
語言:Inglês
出版: 2019
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6834439/
https://ncbi.nlm.nih.gov/pubmed/30711891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2018.12.013
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍